Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Sep;25(9):2743-2755.
doi: 10.1111/dom.15164. Epub 2023 Jun 20.

Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study

Hyeong Kyu Park  1 , Kyoung-Ah Kim  2 , Kyung-Wan Min  3 , Tae-Seo Sohn  4 , In Kyung Jeong  5 , Chul Woo Ahn  6 , Nan-Hee Kim  7 , Ie Byung Park  8 , Ho Chan Cho  9 , Choon Hee Chung  10 , Sung Hee Choi  11 , Kang Seo Park  12 , Seoung-Oh Yang  13 , Kwan Woo Lee  14
Affiliations
Randomized Controlled Trial

Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study

Hyeong Kyu Park et al. Diabetes Obes Metab. 2023 Sep.

Abstract

Aims: To evaluate the effect of dapagliflozin on body composition such as total body fat (BF) mass, abdominal visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) areas compared with glimepiride in Korean patients with type 2 diabetes.

Materials and methods: This was a 52-week, multicentre, randomized, parallel-group, open-label, Phase IV (NCT02564926) study. Patients with inadequate glycaemic control (glycated haemoglobin ≥7.0% and <10.0%) on metformin monotherapy (≥1000 mg/day) were randomized 1:1 to receive dapagliflozin 10 mg/day or glimepiride 1-2 mg/day for 12 months as an add-on to metformin. Baseline and end of study body composition evaluations included dual-energy X-ray absorptiometry and abdominal computed tomography scans.

Results: Of 124 enrolled patients from 14 centres, 121 received study treatment (dapagliflozin: 60; glimepiride: 61) and 106 (85.5%) completed the study. Over 52 weeks, the dapagliflozin group showed the following differences versus the glimepiride group: -2.59 kg BF mass, -1.94% BF%, -17.55 cm2 VAT area, -18.39 cm2 SAT area, -0.46% glycated haemoglobin, -18.25 mg/dl fasting blood glucose, -3.7 kg weight, -2.21 cm waist circumference, -1.37 kg/m2 body mass index, -6.81 mmHg systolic blood pressure and +657.71 ng/ml in adiponectin; all were statistically significant. Both groups had similar incidences of adverse events; however, hypoglycaemic events were mainly (12 of 15) reported in the glimepiride group.

Conclusion: Dapagliflozin reduced total BF mass, abdominal VAT and SAT areas, and showed better glycaemic control than glimepiride. Being safe and well-tolerated, dapagliflozin appears to be a more favourable alternative to sulphonylureas as add-on therapy after metformin monotherapy failure in Korean patients with type 2 diabetes.

Keywords: SGLT2 inhibitor; dapagliflozin; sulphonylureas; type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Heshka S, Ruggiero A, Bray GA, et al. Altered body composition in type 2 diabetes mellitus. Int J Obes (Lond). 2008;32(5):780-787. doi:10.1038/sj.ijo.0803802
    1. Chen Y, He D, Yang T, et al. Relationship between body composition indicators and risk of type 2 diabetes mellitus in Chinese adults. BMC Public Health. 2020;20(1):452. doi:10.1186/s12889-020-08552-5
    1. Escobedo-de la Peña J, Ramírez-Hernández JA, Fernández-Ramos MT, González-Figueroa E, Champagne B. Body fat percentage rather than body mass index related to the high occurrence of type 2 diabetes. Arch Med Res. 2020;51(6):564-571. doi:10.1016/j.arcmed.2020.05.010
    1. Oh TJ, Lee JE, Choi SH, Jang HC. Association between body fat and diabetic peripheral neuropathy in middle-aged adults with type 2 diabetes mellitus: a preliminary report. J Obes Metab Syndr. 2019;28(2):112-117. doi:10.7570/jomes.2019.28.2.112
    1. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498. doi:10.1007/s00125-018-4729-5

Publication types